To the Editor, With great interest, we read an article entitled "Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer", which was recently written by Mu et al. and published in Breast Cancer Res Treat [1] . In this article, they evaluated the prognostic significance of CAML in the cases of metastatic breast cancer (MBC). They found that CAMLs is an independent prognostic biomarker at baseline for the patients with MBC. Even though we approve of their application of this biomarker to the challenging prediction of the prognosis of the patients with MBC, we deem that certain significant problems should be solved before their conclusions can be recognized. In our opinion, the first and most important limitation of their study is that their inclusion criteria were indistinct. In the cases of MBC, prognosis strongly depends on age, viscera function, the location and size of metastatic tumor, pathologic types, and treatment history [2] . For instance, the prognoses of bone metastasis and visceral metastasis are obviously different, even though both of them are metastatic breast cancers [3] . Therefore, it is of great importance to judge whether those patients involved in their study were comparable. The authors should analyze other factors that may affect prognosis, and set clear inclusion criteria. Additionally, the blood samples utilized for the counting of CAMLs and circulating tumor cells (CTCs) were obtained from patients as baseline samples before starting a new therapy, whether the initial
